Bristol-Myers Squibb discusses dapagliflozin study

Bristol-Myers Squibb looks forward to further studies of dapagliflozin to fully understand its potential for patients with type two diabetes.

Findings from a clinical study showed that the novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor had a number of “meaningful” reductions across all key glycemic measures.

The studies also showed those who received the medication experienced a greater reduction in body weight compared to individuals who were given the placebo.

By hindering the re-absorption of glucose in the kidney, the inhibitor ? which is under joint development by Bristol-Myers Squibb and AstraZeneca – reduces the return of filtered glucose to the circulation.

Elisabeth Svanberg, vice president of the former’s development lead department, commented: “These data suggest that dapagliflozin ? may reduce important glycemic measures and facilitate weight loss in patients with type two diabetes.”

She pointed out it was the first SGLT2 to be studied in Phase III clinical investigations.

The biopharmaceutical company presented at the Cowen and Company 29th Annual Health Care Conference on March 17th, a recorded video of which is available to view on the firm’s investor relation website.